https://www.pharmaradar360.com/article/medicaid-program-community-engagement-requirement-for-certain-individuals-1d26d189434b3bfePharma Surgeen2026-06-29T00:00:00.000ZMedicaid Program; Community Engagement Requirement for Certain Individualshttps://www.pharmaradar360.com/article/medical-devices-orthopedic-devices-classification-of-the-medial-knee-implanted-s-fd100919342a44b7Pharma Surgeen2026-06-29T00:00:00.000ZMedical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Absorberhttps://www.pharmaradar360.com/article/cellular-tissue-and-gene-therapies-advisory-committee-notice-of-meeting-establis-294eb2e757dd644ePharma Surgeen2026-06-29T00:00:00.000ZCellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125842 From Capricor, Inc. for Deramiocel (Human Allogeneic Cardiosphere-Derived Cells)https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-d5bbe70ce274cde2Pharma Surgeen2026-06-29T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-1d3e91a0a7e5b991Pharma Surgeen2026-06-29T00:00:00.000ZAgency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Rural Health Care Coordination Program Performance Improvement Measures, OMB No. 0906-0024-Revisionhttps://www.pharmaradar360.com/article/advisory-committee-on-breast-cancer-in-young-women-notice-of-charter-renewal-0634329210e3cc44Pharma Surgeen2026-06-29T00:00:00.000ZAdvisory Committee on Breast Cancer in Young Women; Notice of Charter Renewalhttps://www.pharmaradar360.com/article/establishment-registration-and-product-listing-for-tobacco-products-6e6b342c075c962aPharma Surgeen2026-06-29T00:00:00.000ZEstablishment Registration and Product Listing for Tobacco Productshttps://www.pharmaradar360.com/article/office-of-the-director-national-institutes-of-health-notice-of-closed-meeting-46b7ba8a4b47d3b3Pharma Surgeen2026-06-29T00:00:00.000ZOffice of the Director, National Institutes of Health; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vyale-8ca1eed56c7ae4d1Pharma Surgeen2026-06-29T00:00:00.000ZDetermination of Regulatory Review Period for Purposes of Patent Extension; VYALEVhttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-bc4ab3d843985ba0Pharma Surgeen2026-06-29T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Specieshttps://www.pharmaradar360.com/article/national-heart-lung-and-blood-institute-notice-of-closed-meeting-21960810b2679d58Pharma Surgeen2026-06-29T00:00:00.000ZNational Heart, Lung, and Blood Institute; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/national-institute-of-environmental-health-sciences-notice-of-meeting-6029d027a108b490Pharma Surgeen2026-06-29T00:00:00.000ZNational Institute of Environmental Health Sciences; Notice of Meetinghttps://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-425f2800aae3c69bPharma Surgeen2026-06-29T00:00:00.000ZCenter for Scientific Review; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/the-overlooked-reason-why-new-drugs-take-so-long-and-the-10-trillion-fix-5b8e269c75894b7fPharma Surgeen2026-06-28T15:51:46.000ZThe overlooked reason why new drugs take so long—and the $10 trillion fixhttps://www.pharmaradar360.com/article/teva-pharmaceutical-s-innovative-shift-continues-with-ecopipam-addition-nyse-tev-cff52243bf702955Pharma Surgeen2026-06-28T15:01:39.000ZTeva Pharmaceutical's Innovative Shift Continues With Ecopipam Addition (NYSE:TEVA)https://www.pharmaradar360.com/article/maharashtra-fda-busts-rs-52-lakh-expired-food-racket-fir-filed-against-amazon-wa-a7d0df7c51761094Pharma Surgeen2026-06-28T14:45:00.000ZMaharashtra FDA busts Rs 52-lakh expired food racket; FIR filed against Amazon warehouse officialshttps://www.pharmaradar360.com/article/fda-approves-first-single-dose-generic-treatment-for-influenza-64cb8243589832acPharma Surgeen2026-06-28T14:30:00.000ZFDA approves first single-dose generic treatment for influenzahttps://www.pharmaradar360.com/article/10-best-biotech-stocks-to-buy-according-to-analysts-7a8f0a1dfa669d3cPharma Surgeen2026-06-28T14:21:43.000Z10 Best Biotech Stocks to Buy According to Analystshttps://www.pharmaradar360.com/article/5-best-biotech-stocks-to-buy-according-to-analysts-a9d7e0016abac546Pharma Surgeen2026-06-28T14:21:43.000Z5 Best Biotech Stocks to Buy According to Analystshttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-vytrus-biotech-sa-bme-vyt-2971f32699c8b8fdPharma Surgeen2026-06-28T14:20:14.000ZPrice to earnings forward of Vytrus Biotech SA – BME:VYThttps://www.pharmaradar360.com/article/russian-strike-damages-kyiv-pharmaceutical-plant-during-attack-f1a7ea22a6702b18Pharma Surgeen2026-06-28T14:02:53.000ZRussian Strike Damages Kyiv Pharmaceutical Plant During Attackhttps://www.pharmaradar360.com/article/hackensack-meridian-health-joins-phase-3-trial-of-pfizer-s-investigational-c-dif-7ff0c6a79882ef3aPharma Surgeen2026-06-28T13:36:15.000ZHackensack Meridian Health Joins Phase 3 Trial of Pfizer’s Investigational C difficile Vaccinehttps://www.pharmaradar360.com/article/russian-strike-damaged-darnytsia-pharmaceutical-plant-in-kyiv-no-casualties-685a1547424654e7Pharma Surgeen2026-06-28T13:33:20.000ZRussian strike damaged Darnytsia pharmaceutical plant in Kyiv, no casualtieshttps://www.pharmaradar360.com/article/generic-enzalutamide-tablets-granted-tentative-fda-approval-for-prostate-cancer-af75013723ae327fPharma Surgeen2026-06-28T12:50:41.000ZGeneric Enzalutamide Tablets Granted Tentative FDA Approval for Prostate Cancerhttps://www.pharmaradar360.com/article/gas-chromatography-systems-market-forecast-points-higher-toward-2035-driven-by-p-09bb7beb506d669cPharma Surgeen2026-06-28T12:23:05.000ZGas Chromatography Systems Market Forecast Points Higher Toward 2035, Driven by Pharmaceutical Quality Mandateshttps://www.pharmaradar360.com/article/fda-leadership-s-blind-spots-leads-to-a-surge-in-medical-device-and-drug-recalls-a02b6651abdf64c8Pharma Surgeen2026-06-28T12:11:29.000ZFDA Leadership’s “Blind Spots” Leads to a Surge in Medical Device and Drug Recallshttps://www.pharmaradar360.com/article/fda-conducts-surprise-inspection-at-parbhani-girls-hostel-kitchen-checks-food-sa-ba8a31b65baa50cePharma Surgeen2026-06-28T10:37:47.000ZFDA Conducts Surprise Inspection At Parbhani Girls Hostel Kitchen, Checks Food Safetyhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-veraxa-biotech-ag-nasdaq-vrxaw-e56ce4f87cc7132dPharma Surgeen2026-06-28T10:36:26.000ZPrice to earnings forward of Veraxa Biotech AG – NASDAQ:VRXAWhttps://www.pharmaradar360.com/article/phase-3-trident-trial-misses-survival-end-point-in-glioblastoma-a39cdd0fbac6be82Pharma Surgeen2026-06-28T10:09:11.000ZPhase 3 TRIDENT Trial Misses Survival End Point in Glioblastomahttps://www.pharmaradar360.com/article/russians-hit-pharmaceutical-manufacturer-darnytsia-in-kyiv-557095a7bb5231fdPharma Surgeen2026-06-28T10:00:00.000ZRussians hit pharmaceutical manufacturer Darnytsia in Kyivhttps://www.pharmaradar360.com/article/a-cfo-departure-a-clinical-miss-a-43-billion-question-mark-should-you-throw-in-t-b0290043f6d63aabPharma Surgeen2026-06-28T09:30:00.000ZA CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock?https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-jeil-pharmaceutical-co-ltd-krx-271980-cf640c7094a0a6e3Pharma Surgeen2026-06-28T09:26:35.000ZEnterprise value to revenue forward of Jeil Pharmaceutical Co. Ltd. – KRX:271980https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-ultragenyx-pharmaceutical-inc-nasdaq-rare-6c5ed099781b6849Pharma Surgeen2026-06-28T09:21:37.000ZEnterprise value to revenue forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RAREhttps://www.pharmaradar360.com/article/price-to-book-forward-of-hangzhou-alltest-biotech-co-ltd-class-a-sse-688606-ddf2ea1bda90bda1Pharma Surgeen2026-06-28T08:41:05.000ZPrice to book forward of Hangzhou Alltest Biotech Co., Ltd. Class A – SSE:688606https://www.pharmaradar360.com/article/is-viking-therapeutics-stock-a-no-brainer-buy-below-35-db263bf6683fa0c3Pharma Surgeen2026-06-28T07:35:46.000ZIs Viking Therapeutics stock a no-brainer buy below $35?https://www.pharmaradar360.com/article/inside-the-high-stakes-gamble-to-revive-tanked-biotech-opthea-56d08228815244e0Pharma Surgeen2026-06-28T07:30:43.000ZInside the high-stakes gamble to revive tanked biotech Optheahttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-kyongbo-pharmaceutical-co-ltd-krx-214390-1a54e593f213e2ffPharma Surgeen2026-06-28T06:54:37.000ZEnterprise value to revenue forward of Kyongbo Pharmaceutical Co., Ltd. – KRX:214390https://www.pharmaradar360.com/article/price-to-earnings-forward-of-kyongbo-pharmaceutical-co-ltd-krx-214390-5aa45583984bfac5Pharma Surgeen2026-06-28T06:51:10.000ZPrice to earnings forward of Kyongbo Pharmaceutical Co., Ltd. – KRX:214390https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-jilin-aodong-pharmaceutical-group-co-ltd-cla-9c8bb0fca355dea0Pharma Surgeen2026-06-28T06:30:33.000ZEnterprise value to EBIT forward of Jilin Aodong Pharmaceutical Group Co., Ltd. Class A – SZSE:000623https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-kyongbo-pharmaceutical-co-ltd-krx-214390-257efcdc6a05921ePharma Surgeen2026-06-28T06:30:30.000ZEnterprise value to EBIT forward of Kyongbo Pharmaceutical Co., Ltd. – KRX:214390https://www.pharmaradar360.com/article/price-to-earnings-forward-of-jeil-pharmaceutical-co-ltd-krx-271980-cabb755cc67f2743Pharma Surgeen2026-06-28T06:19:03.000ZPrice to earnings forward of Jeil Pharmaceutical Co. Ltd. – KRX:271980https://www.pharmaradar360.com/article/price-to-earnings-forward-of-towa-pharmaceutical-co-ltd-tse-4553-ef0419de45c3c28aPharma Surgeen2026-06-28T06:15:00.000ZPrice to earnings forward of Towa Pharmaceutical Co., Ltd. – TSE:4553https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-jilin-aodong-pharmaceutical-group-co-ltd-c-d088ea3b9eb49077Pharma Surgeen2026-06-28T06:04:21.000ZEnterprise value to EBITDA forward of Jilin Aodong Pharmaceutical Group Co., Ltd. Class A – SZSE:000623https://www.pharmaradar360.com/article/price-to-sales-forward-of-owc-pharmaceutical-research-corp-otc-owcp-30a46862da066361Pharma Surgeen2026-06-28T05:58:34.000ZPrice to sales forward of OWC PHARMACEUTICAL RESEARCH CORP – OTC:OWCPhttps://www.pharmaradar360.com/article/price-to-book-forward-of-jeil-pharmaceutical-co-ltd-krx-271980-c51b0bb77d3685baPharma Surgeen2026-06-28T05:52:51.000ZPrice to book forward of Jeil Pharmaceutical Co. Ltd. – KRX:271980https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-jeil-pharmaceutical-co-ltd-krx-271980-fefd48f3ecebedb9Pharma Surgeen2026-06-28T05:46:17.000ZEnterprise value to EBIT forward of Jeil Pharmaceutical Co. Ltd. – KRX:271980https://www.pharmaradar360.com/article/number-of-shareholders-of-zhejiang-huahai-pharmaceutical-co-ltd-class-a-sse-6005-0f3f463ba2acd26cPharma Surgeen2026-06-28T05:31:13.000ZNumber of shareholders of Zhejiang Huahai Pharmaceutical Co., Ltd. Class A – SSE:600521https://www.pharmaradar360.com/article/price-to-sales-forward-of-jeil-pharmaceutical-co-ltd-krx-271980-636a9bc1a69b4d94Pharma Surgeen2026-06-28T05:28:43.000ZPrice to sales forward of Jeil Pharmaceutical Co. Ltd. – KRX:271980https://www.pharmaradar360.com/article/why-is-the-us-targeting-germany-s-drug-industry-751043cbd7a52576Pharma Surgeen2026-06-28T05:17:55.000ZWhy is the US targeting Germany's drug industry?https://www.pharmaradar360.com/article/dw-news-people-living-in-the-us-pay-up-to-three-times-more-for-medicine-than-eur-50fc228b9e246f98Pharma Surgeen2026-06-28T05:00:23.000ZDW News. . People living in the US pay up to three times more for medicine than Europeans. Donald Trump says Europe is to blame — but the reality is more complicated. #dwbusinesshttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-hwail-pharmaceutical-co-ltd-krx-061250-1f0312a0ad116c68Pharma Surgeen2026-06-28T04:43:53.000ZEnterprise value to EBITDA forward of Hwail Pharmaceutical Co., Ltd. – KRX:061250https://www.pharmaradar360.com/article/brivaracetam-market-restructuring-competition-focuses-on-sales-power-and-early-m-125067c7780faed4Pharma Surgeen2026-06-28T04:40:00.000ZBrivaracetam Market Restructuring: Competition Focuses on Sales Power and Early Market Entryhttps://www.pharmaradar360.com/article/legend-biotech-legn-reports-lb2501-progress-is-the-stock-still-cheap-cc070817fd833036Pharma Surgeen2026-06-28T04:21:40.000ZLegend Biotech (LEGN) Reports LB2501 Progress, Is The Stock Still Cheap?https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-zhejiang-huahai-pharmaceutical-co-ltd-class-c99879ce088b3a7bPharma Surgeen2026-06-28T03:36:44.000ZEnterprise value to EBIT forward of Zhejiang Huahai Pharmaceutical Co., Ltd. Class A – SSE:600521https://www.pharmaradar360.com/article/price-to-sales-forward-of-zhejiang-huahai-pharmaceutical-co-ltd-class-a-sse-6005-7eb150c9246663cfPharma Surgeen2026-06-28T03:11:14.000ZPrice to sales forward of Zhejiang Huahai Pharmaceutical Co., Ltd. Class A – SSE:600521https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-trinity-biotech-plc-nasdaq-trib-5b6ff068dc9c67d5Pharma Surgeen2026-06-28T02:37:37.000ZEnterprise value to EBITDA forward of Trinity Biotech plc – NASDAQ:TRIBhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-trinity-biotech-plc-nasdaq-trib-04850e62efd2b04ePharma Surgeen2026-06-28T02:28:14.000ZEnterprise value to EBIT forward of Trinity Biotech plc – NASDAQ:TRIBhttps://www.pharmaradar360.com/article/why-this-mid-cap-biotech-could-be-the-dark-horse-threat-to-eli-lilly-and-novo-no-5d6684b7cd4d6536Pharma Surgeen2026-06-28T02:20:41.000ZWhy This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordiskhttps://www.pharmaradar360.com/article/sls-stock-rallies-ahead-of-aml-trial-readout-pharma-bro-martin-shkreli-says-he-s-4fa9eb9f47644bd1Pharma Surgeen2026-06-28T01:08:49.000ZSLS Stock Rallies Ahead Of AML Trial Readout — ‘Pharma Bro’ Martin Shkreli Says He’s Still ‘Very Bearish,’ Predicts Drug Will Failhttps://www.pharmaradar360.com/article/us-texas-biotech-firm-to-build-noah-s-ark-for-endangered-species-fd6262a7ebfd0245Pharma Surgeen2026-06-28T01:06:18.000ZUS, Texas biotech firm to build 'Noah's Ark' for endangered specieshttps://www.pharmaradar360.com/article/this-little-known-biotech-just-delivered-a-bigger-ipo-pop-than-spacex-and-regene-5091cadf9f1dbd6ePharma Surgeen2026-06-28T01:00:00.000ZThis Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Investedhttps://www.pharmaradar360.com/article/price-to-sales-forward-of-zhejiang-jiuzhou-pharmaceutical-co-ltd-class-a-sse-603-bddafb76d7c93c87Pharma Surgeen2026-06-28T00:53:30.000ZPrice to sales forward of Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A – SSE:603456https://www.pharmaradar360.com/article/shara-avis-pecoraro-biotech-is-global-but-we-all-have-the-same-goal-help-patient-7d24df42456de30dPharma Surgeen2026-06-28T00:51:35.000ZShara Avis Pecoraro: Biotech Is Global, but We All Have the Same Goal – Help Patientshttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-zhejiang-jiuzhou-pharmaceutical-co-ltd-class-a-sse-93714fa25ba86ce2Pharma Surgeen2026-06-28T00:51:01.000ZPrice to earnings forward of Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A – SSE:603456https://www.pharmaradar360.com/article/this-little-known-biotech-just-delivered-a-bigger-ipo-pop-than-spacex-and-regene-857888f559f77a84Pharma Surgeen2026-06-28T00:35:23.000ZThis Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Investedhttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32Pharma Surgeen2026-06-28T00:34:25.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/this-little-known-biotech-just-delivered-a-bigger-ipo-pop-than-spacex-and-regene-41e5b9f830917019Pharma Surgeen2026-06-28T00:20:00.000ZThis Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Investedhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-42ce56b723008403Pharma Surgeen2026-06-28T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-ad70a7c774942d33Pharma Surgeen2026-06-28T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-19dd80d71b1a3250Pharma Surgeen2026-06-28T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-60402036ee72836bPharma Surgeen2026-06-28T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-d4ee0e4ac4cfefe5Pharma Surgeen2026-06-28T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-9cfb11c5963ead43Pharma Surgeen2026-06-28T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-c4c4b1af1242dd54Pharma Surgeen2026-06-28T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-82a129a4df15ef16Pharma Surgeen2026-06-28T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-b5a6d18d168ec8a4Pharma Surgeen2026-06-28T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-4e02d85322512fe7Pharma Surgeen2026-06-28T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-752c4b1145bc877aPharma Surgeen2026-06-28T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-b74d85522c454052Pharma Surgeen2026-06-28T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-e29e6884e8573c58Pharma Surgeen2026-06-28T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-52d18ef8c349bc40Pharma Surgeen2026-06-28T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/development-and-clinical-deployment-of-the-systematic-urgent-team-response-in-th-e3c668d7226cb55aPharma Surgeen2026-06-28T00:00:00.000ZDevelopment and Clinical Deployment of the Systematic Urgent Team Response in the Operating Room (SUTO) Protocol for Intraoperative Massive Hemorrhage: A Technical Reporthttps://www.pharmaradar360.com/article/legal-analysis-of-artificial-intelligence-regulation-as-a-clinical-decision-supp-456f546601c57fa5Pharma Surgeen2026-06-28T00:00:00.000ZLEGAL ANALYSIS OF ARTIFICIAL INTELLIGENCE REGULATION AS A CLINICAL DECISION SUPPORT SYSTEM IN INDONESIAN HOSPITALS: CHALLENGES, ACCOUNTABILITY, AND REGULATORY REFORMhttps://www.pharmaradar360.com/article/improving-student-learning-at-sman-2-regarding-the-general-ledger-and-trial-bala-fd12ff495929a32ePharma Surgeen2026-06-28T00:00:00.000ZImproving Student Learning at SMAN 2 Regarding the General Ledger and Trial Balance Worksheetshttps://www.pharmaradar360.com/article/infection-prevention-and-control-systems-in-nigerian-tertiary-hospitals-a-system-1884395951293648Pharma Surgeen2026-06-28T00:00:00.000ZInfection Prevention and Control Systems in Nigerian Tertiary Hospitals: A Systematic Review Study of Policy Implementation and Clinical Outcomeshttps://www.pharmaradar360.com/article/analisis-faktor-yang-mempengaruhi-kepatuhan-implementasi-cara-distribusi-obat-ya-6b848dd50db7a6e1Pharma Surgeen2026-06-28T00:00:00.000ZANALISIS FAKTOR YANG MEMPENGARUHI KEPATUHAN IMPLEMENTASI CARA DISTRIBUSI OBAT YANG BAIK (CDOB) PADA PEDAGANG BESAR FARMASI DI KOTA CIREBONhttps://www.pharmaradar360.com/article/effects-of-a-transformative-learning-theory-based-health-literacy-enhancement-pr-97e524fa07ffeeb1Pharma Surgeen2026-06-28T00:00:00.000ZEffects of a transformative learning theory-based health literacy enhancement program on self-management behaviors and blood pressure in adults with uncontrolled hypertension in Thailand: A cluster randomized controlled trialhttps://www.pharmaradar360.com/article/effects-of-medagogy-based-health-literacy-enhancement-on-self-management-behavio-0c8a34f814a6663cPharma Surgeen2026-06-28T00:00:00.000ZEffects of medagogy-based health literacy enhancement on self-management behaviors and functional capacity among older persons with chronic heart failure: A randomized controlled trialhttps://www.pharmaradar360.com/article/the-effect-of-a-self-management-program-through-a-mobile-application-on-lipid-pr-92d49b73112c79eaPharma Surgeen2026-06-28T00:00:00.000ZThe effect of a self-management program through a mobile application on lipid profile among persons with coronary artery disease: A randomized controlled trial study in Thailandhttps://www.pharmaradar360.com/article/effectiveness-of-lay-counselor-delivered-intervention-for-trauma-related-symptom-bdb3d5a51e7811bfPharma Surgeen2026-06-28T00:00:00.000ZEffectiveness of lay counselor-delivered intervention for trauma-related symptoms in conflict- affected populations: a cluster randomized trial in Iraqhttps://www.pharmaradar360.com/article/malaria-prevalence-and-molecular-markers-of-plasmodium-falciparum-antimalarial-d-416b9b6359170351Pharma Surgeen2026-06-28T00:00:00.000ZMalaria prevalence and molecular markers of Plasmodium falciparum antimalarial drug resistance among mobile populations in malaria-endemic countries: A systematic review and meta-analysishttps://www.pharmaradar360.com/article/inproteamed-interprofessional-clinical-assessment-in-the-emergency-department-a-8f2cd4b3c586b109Pharma Surgeen2026-06-28T00:00:00.000ZinproTeamED - Interprofessional clinical assessment in the emergency department: A qualitative analysishttps://www.pharmaradar360.com/article/initial-outpatient-clinical-characteristics-associated-with-subsequent-conversio-6bb9446ddc94f8d5Pharma Surgeen2026-06-28T00:00:00.000ZInitial outpatient clinical characteristics associated with subsequent conversion from mild cognitive impairment to dementia: a retrospective exploratory studyhttps://www.pharmaradar360.com/article/application-of-propensity-score-methods-to-address-missing-data-in-a-trial-on-th-1a18fb6aa4367946Pharma Surgeen2026-06-28T00:00:00.000ZApplication of Propensity Score Methods to Address Missing Data in a Trial on the Effect of Energy Protein Supplementation Among Pulmonary TB-HIV Patients in Mwanza, Tanzaniahttps://www.pharmaradar360.com/article/reclassification-of-variants-of-uncertain-significance-in-brca1-brca2-and-palb2-79129580d983ba15Pharma Surgeen2026-06-28T00:00:00.000ZReclassification of Variants of Uncertain Significance in BRCA1, BRCA2, and PALB2: Implications for Clinical Decision-Making in Breast Cancerhttps://www.pharmaradar360.com/article/clinical-characteristics-and-risk-factors-in-dry-eye-disease-secondary-to-chroni-4e0cd4d357805567Pharma Surgeen2026-06-28T00:00:00.000ZClinical characteristics and risk factors in dry eye disease secondary to chronic graft-versus-host: A Comparative Cross-Sectional Studyhttps://www.pharmaradar360.com/article/combined-use-of-etomidate-and-propofol-reduce-the-duration-of-apnea-vs-propofol-9e49894d7d647c11Pharma Surgeen2026-06-28T00:00:00.000ZCombined use of etomidate and propofol reduce the duration of apnea vs propofol along in patients undergoing hysteroscopy: a randomised double-blind trialhttps://www.pharmaradar360.com/article/distribution-of-citalopram-enantiomers-following-medication-with-racemic-citalop-8bf6cc8d9a92afa3Pharma Surgeen2026-06-28T00:00:00.000ZDistribution of citalopram enantiomers following medication with racemic citalopram - a naturalistic therapeutic drug monitoring studyhttps://www.pharmaradar360.com/article/effectiveness-of-a-novel-mobile-health-application-in-educating-first-time-compl-162c1bae1b993dacPharma Surgeen2026-06-28T00:00:00.000ZEffectiveness of a novel mobile health application in educating first time complete denture wearers: a prospective clinical studyhttps://www.pharmaradar360.com/article/mri-radiomics-for-the-prediction-of-histologic-grade-in-bladder-cancer-533ee201da9bd214Pharma Surgeen2026-06-28T00:00:00.000ZMRI radiomics for the prediction of histologic grade in bladder cancerhttps://www.pharmaradar360.com/article/antimicrobial-resistance-surveillance-of-clinical-isolates-collected-from-paedia-0799bb0ec674f2a8Pharma Surgeen2026-06-28T00:00:00.000ZAntimicrobial resistance surveillance of clinical isolates collected from paediatric and adult patients of intensive care units in China from 2017 to 2022https://www.pharmaradar360.com/article/barbed-versus-traditional-sutures-in-primary-total-knee-arthroplasty-systematic-50e1f4b274645731Pharma Surgeen2026-06-28T00:00:00.000ZBarbed versus traditional sutures in primary total knee arthroplasty: systematic review and meta-analysis of clinical outcomes and wound-related complicationshttps://www.pharmaradar360.com/article/clinical-outcomes-after-the-implementation-of-a-patient-centered-care-program-ap-65d6ecf64ed3a267Pharma Surgeen2026-06-28T00:00:00.000ZClinical outcomes after the implementation of a patient-centered care program applied to newly admitted people with HIV in Mexico City: a retrospective cohort studyhttps://www.pharmaradar360.com/article/integrating-lipometabolic-and-adiposity-indices-to-enhance-risk-stratification-f-1365657d3ef9cffdPharma Surgeen2026-06-28T00:00:00.000ZIntegrating lipometabolic and adiposity indices to enhance risk stratification for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: clinical utility and interplay between triglyceride-glucose body mass index and low-density lipoprotein cholesterolhttps://www.pharmaradar360.com/article/severe-acute-hepatitis-induced-by-combined-rosuvastatin-and-ticagrelor-therapy-p-06ae7d8cbb742140Pharma Surgeen2026-06-28T00:00:00.000ZSevere Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosishttps://www.pharmaradar360.com/article/can-multilingual-environments-promote-scalable-edtech-evidence-from-a-randomized-3d814ac2dcd1772fPharma Surgeen2026-06-28T00:00:00.000ZCan Multilingual Environments Promote Scalable EdTech? Evidence from a Randomized Controlled Trialhttps://www.pharmaradar360.com/article/a-large-scale-randomized-control-trial-showing-llm-generated-feedback-helps-low-3eb5fa632aa13e45Pharma Surgeen2026-06-28T00:00:00.000ZA Large Scale Randomized Control Trial Showing LLM Generated Feedback Helps Low-Knowledge Middle School Math Students with Short-Term Learninghttps://www.pharmaradar360.com/article/letter-assessing-pruritus-efficacy-with-peroxisome-proliferator-activated-recept-7343187ce70aba6bPharma Surgeen2026-06-28T00:00:00.000ZLetter: Assessing Pruritus Efficacy With Peroxisome Proliferator‐Activated Receptor Agonists in Primary Biliary Cholangitis Must Include Grading the Strength of Trial Evidencehttps://www.pharmaradar360.com/article/effects-of-concurrent-transcranial-direct-current-stimulation-and-robotic-lower-cd500e8ff0caf718Pharma Surgeen2026-06-28T00:00:00.000ZEffects of concurrent transcranial direct current stimulation and robotic lower-limb training on motor recovery after stroke: a randomized sham-controlled trialhttps://www.pharmaradar360.com/article/spontaneous-regression-of-colorectal-liver-metastasis-with-coexisting-igg4-rich-a68a241ac893c283Pharma Surgeen2026-06-28T00:00:00.000ZSpontaneous regression of colorectal liver metastasis with coexisting IgG4-rich inflammatory pseudotumor-like changes: a case reporthttps://www.pharmaradar360.com/article/a-case-of-small-pancreatic-neuroendocrine-tumor-of-less-than-10-mm-showing-metas-2fe0ccfaf8532014Pharma Surgeen2026-06-28T00:00:00.000ZA case of small pancreatic neuroendocrine tumor of less than 10 mm showing metastasis to multiple organshttps://www.pharmaradar360.com/article/association-between-mental-health-of-patients-with-work-related-injury-and-their-8a0ce07bcb1102d3Pharma Surgeen2026-06-28T00:00:00.000ZAssociation Between Mental Health of Patients with Work-Related Injury and Their Compensation Claim Status: Exploratory Findings from the IMPRovE Trialhttps://www.pharmaradar360.com/article/pathogens-in-the-bay-environmental-staphylococcus-saprophyticus-strains-mirror-c-1f794e165cd35be5Pharma Surgeen2026-06-28T00:00:00.000ZPathogens in the bay: environmental Staphylococcus saprophyticus strains mirror clinical counterparts in virulence, biofilm formation, antimicrobial resistance, pathogenicity, and phage susceptibilityhttps://www.pharmaradar360.com/article/beyond-the-jak2-mutation-the-inflammasome-clonal-stability-and-the-thrombotic-ni-10ac9b4729043f61Pharma Surgeen2026-06-28T00:00:00.000ZBeyond the JAK2 mutation: The inflammasome, clonal stability, and the thrombotic niche in myeloproliferative neoplasmshttps://www.pharmaradar360.com/article/harnessing-the-gut-microbiome-for-improved-immune-checkpoint-inhibition-in-color-d9264b774896dbd5Pharma Surgeen2026-06-28T00:00:00.000ZHarnessing the gut microbiome for improved immune checkpoint inhibition in colorectal cancer immunotherapy: a narrative Reviewhttps://www.pharmaradar360.com/article/social-appearance-anxiety-and-its-associations-with-anxiety-depressive-symptoms-492e5879a72e6d2bPharma Surgeen2026-06-28T00:00:00.000ZSocial appearance anxiety and its associations with anxiety, depressive symptoms, and health-related quality of life in systemic sclerosis: a cross-sectional studyhttps://www.pharmaradar360.com/article/enhancing-the-treat-to-target-approach-of-inflammatory-arthritis-with-purposeful-b7569fcb66d3ce4ePharma Surgeen2026-06-28T00:00:00.000ZEnhancing the treat-to-target approach of inflammatory arthritis with purposeful shared decision-making: results of a randomized controlled trialhttps://www.pharmaradar360.com/article/pseudomonas-aeruginosa-st4936-with-extensive-antibacterial-drug-resistance-and-v-534590599132ad3aPharma Surgeen2026-06-28T00:00:00.000ZPseudomonas aeruginosa ST4936 with extensive antibacterial drug resistance and virulence determinants from ureteral stent biofilms: whole-genome insightshttps://www.pharmaradar360.com/article/electrochemical-detection-of-heavy-metal-pb-ions-and-pharmaceutical-waste-ciprof-85e31dd1a6243618Pharma Surgeen2026-06-28T00:00:00.000ZElectrochemical Detection of Heavy Metal (Pb Ions) and Pharmaceutical Waste (Ciprofloxacin) in Very Low Concentration Using β‐NaFeO ₂https://www.pharmaradar360.com/article/other-titles-from-iste-in-computer-engineering-6b30f6bf78c6bcc4Pharma Surgeen2026-06-28T00:00:00.000ZOther titles from ISTE in Computer Engineeringhttps://www.pharmaradar360.com/article/index-d8134c5d8b402c02Pharma Surgeen2026-06-28T00:00:00.000ZIndexhttps://www.pharmaradar360.com/article/dynamic-condylar-screw-versus-long-pfn-in-subtrochanteric-fractures-c4d3e917fb42553bPharma Surgeen2026-06-28T00:00:00.000ZDynamic Condylar Screw Versus Long PFN in Subtrochanteric Fractureshttps://www.pharmaradar360.com/article/ai-based-functional-outcome-comparison-of-nails-in-unstable-intertrochanteric-fe-437e9789e55e386bPharma Surgeen2026-06-28T00:00:00.000ZAI‐Based Functional Outcome Comparison of Nails in Unstable Intertrochanteric Femur Fracturehttps://www.pharmaradar360.com/article/alpha-blockers-in-cervical-radiculopathy-54c266677f4a9d53Pharma Surgeen2026-06-28T00:00:00.000ZAlpha‐Blockers in Cervical Radiculopathyhttps://www.pharmaradar360.com/article/fracture-healing-after-cephalomedullary-nailing-with-zoledronic-acid-57bb15a5c7f84599Pharma Surgeen2026-06-28T00:00:00.000ZFracture Healing After Cephalomedullary Nailing with Zoledronic Acidhttps://www.pharmaradar360.com/article/rigid-versus-hybrid-fixation-in-both-bone-forearm-fractures-e9c026013221b155Pharma Surgeen2026-06-28T00:00:00.000ZRigid Versus Hybrid Fixation in Both‐Bone Forearm Fractureshttps://www.pharmaradar360.com/article/designing-nanobots-for-targeted-drug-delivery-and-the-application-of-nanotechnol-d7bdf3506b92cab9Pharma Surgeen2026-06-28T00:00:00.000ZDesigning Nanobots for Targeted Drug Delivery and the Application of Nanotechnology in Modern Medical Advancementshttps://www.pharmaradar360.com/article/ai-driven-drug-discovery-and-personalized-medicine-in-cancer-1d00dbc1d54429dbPharma Surgeen2026-06-28T00:00:00.000ZAI‐Driven Drug Discovery and Personalized Medicine in Cancerhttps://www.pharmaradar360.com/article/heterocyclic-compound-having-herbicides-activity-070e9fe41f7d9380Pharma Surgeen2026-06-28T00:00:00.000ZHeterocyclic Compound Having Herbicides Activityhttps://www.pharmaradar360.com/article/heterocyclic-compounds-as-anticonvulsants-antipyretics-antiallergic-agents-and-a-da07d2fefca6404cPharma Surgeen2026-06-28T00:00:00.000ZHeterocyclic Compounds as Anticonvulsants, Antipyretics, Antiallergic Agents, and Antileprosy Agentshttps://www.pharmaradar360.com/article/heterocyclic-compounds-as-anti-inflammatory-agents-fb4bf96a6338c552Pharma Surgeen2026-06-28T00:00:00.000ZHeterocyclic Compounds as Anti‐Inflammatory Agentshttps://www.pharmaradar360.com/article/heterocyclic-compounds-as-anticancer-agents-5a13d83a3753515bPharma Surgeen2026-06-28T00:00:00.000ZHeterocyclic Compounds as Anticancer Agentshttps://www.pharmaradar360.com/article/heterocyclic-compounds-as-antimicrobial-antibacterial-antifungal-antiviral-and-a-e99ecd99913f0295Pharma Surgeen2026-06-28T00:00:00.000ZHeterocyclic Compounds as Antimicrobial (Antibacterial, Antifungal, Antiviral, and Anthelmintics) Agenthttps://www.pharmaradar360.com/article/synthesis-and-biological-evaluation-of-thiophene-and-piperazine-based-active-com-3ba486ca6f1d8e1ePharma Surgeen2026-06-28T00:00:00.000ZSynthesis and Biological Evaluation of Thiophene‐ and Piperazine‐Based Active Compoundshttps://www.pharmaradar360.com/article/heterocyclic-compounds-as-antihypertensive-agents-a5d4dcdce99b82baPharma Surgeen2026-06-28T00:00:00.000ZHeterocyclic Compounds as Antihypertensive Agentshttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-owc-pharmaceutical-research-corp-otc-owcp-519d636b47fe33a3Pharma Surgeen2026-06-27T23:50:33.000ZPrice to earnings forward of OWC PHARMACEUTICAL RESEARCH CORP – OTC:OWCPhttps://www.pharmaradar360.com/article/price-to-sales-forward-of-ultragenyx-pharmaceutical-inc-nasdaq-rare-d8e3d86987ea258dPharma Surgeen2026-06-27T23:00:48.000ZPrice to sales forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RAREhttps://www.pharmaradar360.com/article/3-biotech-takeover-targets-wall-street-is-watching-after-the-apogee-deal-8e77878bc2dd4c8ePharma Surgeen2026-06-27T22:51:03.000Z3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Dealhttps://www.pharmaradar360.com/article/sitc-leaders-ring-the-nyse-opening-bell-to-commemorate-the-annual-biotech-strate-141694524753f588Pharma Surgeen2026-06-27T22:50:10.000ZSITC Leaders Ring the NYSE Opening Bell to Commemorate the Annual Biotech Strategic Meetinghttps://www.pharmaradar360.com/article/anhui-sunhere-pharmaceutical-excipients-co-ltd-class-a-actuals-estimates-szse-30-d4d2fd0a407c101ePharma Surgeen2026-06-27T22:41:15.000ZAnhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A Actuals & Estimates (SZSE:300452)https://www.pharmaradar360.com/article/lx2006-gene-therapy-fda-supported-accelerated-approval-pathway-and-positive-inte-b1c995bafec5c779Pharma Surgeen2026-06-27T22:35:21.000ZLX2006 Gene Therapy: FDA-Supported Accelerated Approval Pathway and Positive Interim Outcomes in Friedreich Ataxia Cardiomyopathyhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-ok-biotech-co-ltd-twse-4155-4f4caa5c07bb9a4dPharma Surgeen2026-06-27T22:23:05.000ZEnterprise value to EBIT forward of Ok Biotech Co., Ltd. – TWSE:4155https://www.pharmaradar360.com/article/tak-755-from-takeda-pharmaceutical-co-enzyme-replacement-for-a-rare-bleeding-dis-5627a47db023462aPharma Surgeen2026-06-27T22:17:13.000ZTAK-755 from Takeda Pharmaceutical Co. - enzyme replacement for a rare bleeding disorderhttps://www.pharmaradar360.com/article/wall-street-says-johnson-and-johnson-s-fda-approved-psoriasis-drug-should-create-8f65fc7ec96dff41Pharma Surgeen2026-06-27T21:44:38.000ZWall Street says Johnson and Johnson’s FDA-approved psoriasis drug should create 'significant value' for Protagonist Therapeuticshttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-rtw-biotech-opportunities-ltd-usd-aquisuk-rtwl-7fa81d8e98d53e0cPharma Surgeen2026-06-27T21:31:29.000ZPrice to earnings forward of RTW Biotech Opportunities Ltd USD – AQUISUK:RTWLhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-enlie-pharmaceutical-jsc-upcom-bcp-245984b7e6d77c5bPharma Surgeen2026-06-27T21:22:38.000ZEnterprise value to EBITDA forward of ENLIE Pharmaceutical JSC – UPCOM:BCPhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-kobayashi-pharmaceutical-co-ltd-mun-koy-86cc5307209120bbPharma Surgeen2026-06-27T21:16:32.000ZEnterprise value to EBIT forward of Kobayashi Pharmaceutical Co., Ltd. – MUN:KOYhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-aska-pharmaceutical-holdings-co-ltd-tse-4-e43fd278e9e9d36dPharma Surgeen2026-06-27T21:07:12.000ZEnterprise value to revenue forward of ASKA Pharmaceutical Holdings Co., Ltd. – TSE:4886https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-aska-pharmaceutical-holdings-co-ltd-tse-4886-42d8de33fa643a40Pharma Surgeen2026-06-27T21:00:50.000ZEnterprise value to EBIT forward of ASKA Pharmaceutical Holdings Co., Ltd. – TSE:4886https://www.pharmaradar360.com/article/what-to-expect-at-dea-rescheduling-hearing-when-does-marijuana-become-medicine-t-bebe92fc98e99bd9Pharma Surgeen2026-06-27T20:55:00.000ZWhat To Expect At DEA Rescheduling Hearing: When Does Marijuana Become Medicine? The Answer Is Proofhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-fermenta-biotech-ltd-nse-fermenta-06eec746e138a0b5Pharma Surgeen2026-06-27T20:42:56.000ZEnterprise value to EBIT forward of Fermenta Biotech Ltd – NSE:FERMENTAhttps://www.pharmaradar360.com/article/what-to-know-about-this-345-000-enliven-insider-sale-as-the-stock-soars-130-fc2f44293837252aPharma Surgeen2026-06-27T20:36:00.000ZWhat to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-fermenta-biotech-ltd-nse-fermenta-1cce7fc676a60e19Pharma Surgeen2026-06-27T20:22:59.000ZEnterprise value to revenue forward of Fermenta Biotech Ltd – NSE:FERMENTAhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-enlie-pharmaceutical-jsc-upcom-bcp-8a184a8b07854fa7Pharma Surgeen2026-06-27T20:09:39.000ZEnterprise value to EBIT forward of ENLIE Pharmaceutical JSC – UPCOM:BCPhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-towa-pharmaceutical-co-ltd-dus-6qc-6e58e44e329c1de8Pharma Surgeen2026-06-27T20:09:29.000ZPrice to earnings forward of Towa Pharmaceutical Co., Ltd. – DUS:6QChttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-shandong-pharmaceutical-glass-co-ltd-clas-5cb3255110e31e8cPharma Surgeen2026-06-27T20:09:09.000ZEnterprise value to revenue forward of Shandong Pharmaceutical Glass Co., Ltd. Class A – SSE:600529https://www.pharmaradar360.com/article/price-to-book-forward-of-veraxa-biotech-ag-nasdaq-vrxaw-681aeae5e2ed959fPharma Surgeen2026-06-27T19:53:43.000ZPrice to book forward of Veraxa Biotech AG – NASDAQ:VRXAWhttps://www.pharmaradar360.com/article/what-to-know-about-orbimed-s-39-million-enliven-therapeutics-stock-sale-amid-a-1-949a99f90bf841fdPharma Surgeen2026-06-27T19:39:52.000ZWhat to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rallyhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-owc-pharmaceutical-research-corp-otc-owcp-0205df55612ef571Pharma Surgeen2026-06-27T19:27:41.000ZEnterprise value to EBITDA forward of OWC PHARMACEUTICAL RESEARCH CORP – OTC:OWCPhttps://www.pharmaradar360.com/article/2-biotech-stocks-worth-buying-before-their-potential-buyouts-1052f9776f703698Pharma Surgeen2026-06-27T18:45:00.000Z2 Biotech Stocks Worth Buying Before Their Potential Buyoutshttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-heilongjiang-zbd-pharmaceutical-co-ltd-cl-3d73397f67c9c99aPharma Surgeen2026-06-27T18:34:55.000ZEnterprise value to revenue forward of HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A – SSE:603567https://www.pharmaradar360.com/article/2-biotech-stocks-worth-buying-before-their-potential-buyouts-3281a216d6b2ab29Pharma Surgeen2026-06-27T18:22:42.000Z2 Biotech Stocks Worth Buying Before Their Potential Buyoutshttps://www.pharmaradar360.com/article/nvidia-invests-in-generate-biomedicines-targeting-1-8t-market-with-ai-driven-dru-1622a143ba7f6a50Pharma Surgeen2026-06-27T17:47:42.000ZNvidia invests in Generate Biomedicines, targeting $1.8T market with AI-driven drug discoveryhttps://www.pharmaradar360.com/article/generate-biomedicines-stock-ends-week-back-above-ipo-price-as-volume-jumps-0b41b76c30eb08c8Pharma Surgeen2026-06-27T15:27:17.000ZGenerate Biomedicines stock ends week back above IPO price as volume jumpshttps://www.pharmaradar360.com/article/from-milk-to-fruits-fda-finds-expired-items-worth-over-2-35-lakh-in-warehouses-ea8fb5206b2ad38fPharma Surgeen2026-06-27T15:08:29.000ZFrom milk to fruits, FDA finds expired items worth over ₹2.35 lakh in warehouseshttps://www.pharmaradar360.com/article/filling-the-hs-treatment-gap-ruxolitinib-targets-early-stage-disease-3614a3f84e438e04Pharma Surgeen2026-06-27T15:00:00.000ZFilling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Diseasehttps://www.pharmaradar360.com/article/u-s-fda-accepts-snda-for-roflumilast-cream-for-pso-in-young-kids-pdufa-date-set-9f71a9ebcfd493d3Pharma Surgeen2026-06-27T14:57:15.000ZU.S. FDA Accepts sNDA for Roflumilast Cream for PsO in Young Kids; PDUFA Date Set for June 29, 2026.https://www.pharmaradar360.com/article/us-texas-biotech-firm-to-build-noah-s-ark-for-endangered-species-7a3ad7b14f15c443Pharma Surgeen2026-06-27T14:01:46.000ZUS, Texas biotech firm to build 'Noah's Ark' for endangered specieshttps://www.pharmaradar360.com/article/help-stock-crashes-on-anxiety-trial-results-but-here-s-why-jefferies-sees-up-to-145d42874ac0b13fPharma Surgeen2026-06-27T12:35:50.000ZHELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upsidehttps://www.pharmaradar360.com/article/nvidia-owns-this-under-the-radar-20-stock-poised-to-disrupt-a-1-8-trillion-marke-3b42a6e9bc1ee4bfPharma Surgeen2026-06-27T12:23:00.000ZNvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Markethttps://www.pharmaradar360.com/article/nvidia-invests-in-generate-biomedicines-targeting-1-8t-market-with-ai-driven-dru-670e6271e104be16Pharma Surgeen2026-06-27T11:39:02.000ZNvidia invests in Generate Biomedicines, targeting $1.8T market with AI-driven drug discoveryhttps://www.pharmaradar360.com/article/eli-lilly-lly-announces-positive-phase-3-results-for-jaypirca-combination-in-rel-4957fa55dbc22293Pharma Surgeen2026-06-27T11:30:27.000ZEli Lilly (LLY) Announces Positive Phase 3 Results for Jaypirca Combination in Relapsed CLL/SLLhttps://www.pharmaradar360.com/article/eli-lilly-lly-announces-positive-phase-3-results-for-jaypirca-combination-in-rel-3760f3d6a363f5c3Pharma Surgeen2026-06-27T11:26:57.000ZEli Lilly (LLY) Announces Positive Phase 3 Results for Jaypirca Combination in Relapsed CLL/SLLhttps://www.pharmaradar360.com/article/eli-lilly-lly-announces-positive-phase-3-results-for-jaypirca-combination-in-rel-ba529dd6a082fb08Pharma Surgeen2026-06-27T11:21:48.000ZEli Lilly (LLY) Announces Positive Phase 3 Results for Jaypirca Combination in Relapsed CLL/SLLhttps://www.pharmaradar360.com/article/union-bancaire-privee-ubp-sa-sells-44-839-shares-of-teva-pharmaceutical-industri-c89c52883c078968Pharma Surgeen2026-06-27T11:00:15.000ZUnion Bancaire Privee UBP SA Sells 44,839 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-shares-sold-by-sterling-capital-manageme-8c72506783064b85Pharma Surgeen2026-06-27T10:20:02.000ZTeva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Sterling Capital Management LLChttps://www.pharmaradar360.com/article/tvtx-lgnd-stocks-in-spotlight-ahead-of-monday-s-fda-call-on-kidney-drug-filspari-fa6238499aaae213Pharma Surgeen2026-06-27T10:17:52.000ZTVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filsparihttps://www.pharmaradar360.com/article/pfizer-s-seagen-bet-sours-further-china-debate-continues-to-heat-up-and-more-6a355cec07ee49bcPharma Surgeen2026-06-27T10:00:00.000ZPfizer’s Seagen bet sours further; China debate continues to heat up; and morehttps://www.pharmaradar360.com/article/depo-provera-risks-fda-warnings-and-legal-concerns-d358b4cb35c3a531Pharma Surgeen2026-06-27T09:39:03.000ZDepo-Provera: Risks, FDA Warnings and Legal Concernshttps://www.pharmaradar360.com/article/fda-cracks-down-on-illegal-gutkha-adulterated-food-in-pune-198-raids-84-lakh-wor-4a5f416213c0acedPharma Surgeen2026-06-27T09:37:52.000ZFDA Cracks Down On Illegal Gutkha & Adulterated Food In Pune; 198 Raids, ₹84 Lakh Worth Of Gutkha Seized, 92https://www.pharmaradar360.com/article/a-new-obesity-drug-just-reached-human-trials-here-s-what-comes-next-cfe4d30b108dc249Pharma Surgeen2026-06-27T09:29:38.000ZA New Obesity Drug Just Reached Human Trials. Here's What Comes Nexthttps://www.pharmaradar360.com/article/viking-therapeutics-expands-obesity-pipeline-with-vk3019-phase-1-d692896a1e5dba67Pharma Surgeen2026-06-27T09:29:38.000ZViking Therapeutics Expands Obesity Pipeline With VK3019 Phase 1https://www.pharmaradar360.com/article/lupin-secures-us-fda-tentative-approval-for-enzalutamide-tablets-483fb27a549ab126Pharma Surgeen2026-06-27T09:14:37.000ZLupin Secures US FDA Tentative Approval for Enzalutamide Tabletshttps://www.pharmaradar360.com/article/fda-issues-sweeping-crackdown-on-food-safety-violations-across-eateries-810ee41861551593Pharma Surgeen2026-06-27T09:06:50.000ZFDA issues sweeping crackdown on food safety violations across eaterieshttps://www.pharmaradar360.com/article/this-stock-is-up-58-this-year-is-it-too-late-to-buy-657c7797c2370dc2Pharma Surgeen2026-06-27T08:37:03.000ZThis stock is up 58% this year. Is it too late to buy?https://www.pharmaradar360.com/article/price-to-sales-forward-of-sunhawk-vision-biotech-inc-tpex-7759-4290e94c6ded85ecPharma Surgeen2026-06-27T08:32:31.000ZPrice to sales forward of Sunhawk Vision Biotech, Inc. – TPEX:7759https://www.pharmaradar360.com/article/guangzhou-baiyunshan-pharmaceutical-holdings-company-limited-class-h-actuals-est-0dce19bc3291a468Pharma Surgeen2026-06-27T08:02:28.000ZGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H Actuals & Estimates (HKEX:874)https://www.pharmaradar360.com/article/j-j-presents-nipocalimab-data-showing-benefits-in-early-stage-myasthenia-gravis-78118d9506848286Pharma Surgeen2026-06-27T06:53:07.000ZJ&J presents nipocalimab data showing benefits in early-stage myasthenia gravishttps://www.pharmaradar360.com/article/fda-approves-risankizumab-for-pediatric-psoriasis-and-psoriatic-arthritis-3f15fed9041c037cPharma Surgeen2026-06-27T06:53:07.000ZFDA Approves Risankizumab for Pediatric Psoriasis and Psoriatic Arthritishttps://www.pharmaradar360.com/article/global-clinical-trials-are-shifting-east-is-india-ready-to-lead-e21e3a062b58de0fPharma Surgeen2026-06-27T06:43:39.000ZGlobal clinical trials are shifting east. Is India ready to lead?https://www.pharmaradar360.com/article/corcept-gives-fda-new-relacorilant-data-in-resubmitted-application-50c5b6908fe1c5daPharma Surgeen2026-06-27T06:00:09.000ZCorcept gives FDA new relacorilant data in resubmitted applicationhttps://www.pharmaradar360.com/article/price-to-book-forward-of-veraxa-biotech-ag-fwb-j8l0-a6fdf89706035a17Pharma Surgeen2026-06-27T05:55:10.000ZPrice to book forward of Veraxa Biotech AG – FWB:J8L0https://www.pharmaradar360.com/article/haisco-pharmaceutical-group-co-ltd-class-a-actuals-estimates-szse-002653-6fe22a422fee619ePharma Surgeen2026-06-27T04:50:00.000ZHaisco Pharmaceutical Group Co. Ltd. Class A Actuals & Estimates (SZSE:002653)https://www.pharmaradar360.com/article/us-fda-greenlights-viridian-s-thyroid-eye-disease-drug-bb40a4b7e2bccd33Pharma Surgeen2026-06-27T04:02:06.000ZUS FDA greenlights Viridian’s thyroid eye disease drughttps://www.pharmaradar360.com/article/price-to-book-forward-of-sunway-biotech-co-ltd-tpex-1271-8a987b152cd1ef79Pharma Surgeen2026-06-27T03:53:17.000ZPrice to book forward of SunWay Biotech Co., Ltd. – TPEX:1271https://www.pharmaradar360.com/article/fda-issues-complete-response-letter-for-lantheus-net-imaging-drug-by-investing-c-eb8cdc58cd869f4bPharma Surgeen2026-06-27T03:06:46.000ZFDA issues complete response letter for Lantheus’ NET imaging drug By Investing.comhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-purple-biotech-ltd-nasdaq-ppbt-a2813785f8783f30Pharma Surgeen2026-06-27T02:10:06.000ZPrice to earnings forward of Purple Biotech Ltd. – NASDAQ:PPBThttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-cell-biotech-co-ltd-krx-049960-a659745f379cc5b4Pharma Surgeen2026-06-27T02:09:37.000ZPrice to earnings forward of Cell Biotech Co., Ltd – KRX:049960https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-ildong-pharmaceutical-co-ltd-krx-249420-d649922185b47b33Pharma Surgeen2026-06-27T01:59:46.000ZEnterprise value to EBITDA forward of Ildong Pharmaceutical Co., Ltd. – KRX:249420https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-ildong-pharmaceutical-co-ltd-krx-249420-74ad3dbfac9eb848Pharma Surgeen2026-06-27T01:52:21.000ZEnterprise value to EBIT forward of Ildong Pharmaceutical Co., Ltd. – KRX:249420https://www.pharmaradar360.com/article/capricor-therapeutics-announces-fda-advisory-committee-meeting-for-deramiocel-ce-6b21785f1178cf13Pharma Surgeen2026-06-27T01:37:00.000ZCapricor Therapeutics Announces FDA Advisory Committee Meeting for Deramiocel Cell Therapy in Duchenne Muscular Dystrophy – Minicharthttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-cell-biotech-co-ltd-krx-049960-3d8366c87ad6656ePharma Surgeen2026-06-27T01:15:25.000ZEnterprise value to revenue forward of Cell Biotech Co., Ltd – KRX:049960https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-ildong-pharmaceutical-co-ltd-krx-249420-4e1280a11dfc637ePharma Surgeen2026-06-27T00:51:28.000ZEnterprise value to revenue forward of Ildong Pharmaceutical Co., Ltd. – KRX:249420https://www.pharmaradar360.com/article/natera-ntra-partners-with-eledon-to-put-prospera-into-phase-3-kidney-trial-eb3188c243cacf4cPharma Surgeen2026-06-27T00:22:03.000ZNatera (NTRA) Partners With Eledon To Put Prospera Into Phase 3 Kidney Trialhttps://www.pharmaradar360.com/article/redwire-rdw-unveils-octopus-e140-and-completes-iss-biotech-missions-e5ba805e9c0f8170Pharma Surgeen2026-06-27T00:15:00.000ZRedwire (RDW) Unveils Octopus E140 And Completes ISS Biotech Missionshttps://www.pharmaradar360.com/article/the-italian-landscape-of-digital-therapeutics-in-a-european-context-13645a6ddb3f123bPharma Surgeen2026-06-27T00:00:00.000ZThe Italian landscape of digital therapeutics in a European contexthttps://www.pharmaradar360.com/article/pharmacological-characterization-of-sll-022ccp-a-selective-opioid-receptor-agoni-35fb0ddc7d8627f3Pharma Surgeen2026-06-27T00:00:00.000ZPharmacological Characterization of SLL-022CCP, a Selective κ‑Opioid Receptor Agonist with Potent Antinociceptive Effects and Low Central Side Effectshttps://www.pharmaradar360.com/article/next-generation-trem2-targeted-therapies-for-alzheimer-s-disease-insights-and-di-074d26d71d7f952fPharma Surgeen2026-06-27T00:00:00.000ZNext-generation TREM2-targeted therapies for Alzheimer's disease: insights and directions from the INVOKE-2 trialhttps://www.pharmaradar360.com/article/loeffler-s-endocarditis-complicating-crohn-s-disease-associated-hypereosinophili-d3b7940d9126c2f4Pharma Surgeen2026-06-27T00:00:00.000ZLoeffler's endocarditis Complicating Crohn's Disease-Associated Hypereosinophilia: A Fatal Case of Eosinophil-Mediated Restrictive Cardiomyopathyhttps://www.pharmaradar360.com/article/feasibility-of-a-community-centred-approach-to-mapping-alcohol-outlet-density-an-0a7460e48c30821aPharma Surgeen2026-06-27T00:00:00.000ZFeasibility of a community-centred approach to mapping alcohol outlet density and outlet trading times in two South African communitieshttps://www.pharmaradar360.com/article/a-clinical-case-of-ischemic-stroke-in-a-patient-with-bilateral-agenesia-of-the-i-be81f774d890c88bPharma Surgeen2026-06-27T00:00:00.000ZA clinical case of ischemic stroke in a patient with bilateral agenesia of the internal carotid arterieshttps://www.pharmaradar360.com/article/pharmaceutical-e-commerce-sales-forecasting-using-gm-1-1-and-svr-94c3b4e082520f0cPharma Surgeen2026-06-27T00:00:00.000ZPHARMACEUTICAL E-COMMERCE SALES FORECASTING USING GM (1,1) AND SVRhttps://www.pharmaradar360.com/article/smoking-induced-liver-injury-and-related-diseases-molecular-mechanisms-pathogeni-4f32a8e951fc9c25Pharma Surgeen2026-06-27T00:00:00.000ZSmoking-induced liver injury and related diseases: Molecular mechanisms, pathogenic amplification, and clinical implicationshttps://www.pharmaradar360.com/article/new-onset-diabetes-mellitus-after-distal-pancreatectomy-incidence-predictors-and-2ddf00afa4fd0fd2Pharma Surgeen2026-06-27T00:00:00.000ZNew-onset diabetes mellitus after distal pancreatectomy: Incidence, predictors and clinical impacthttps://www.pharmaradar360.com/article/clinical-features-diagnosis-and-treatment-of-colorectal-cap-polyposis-f5701edfcbecb83cPharma Surgeen2026-06-27T00:00:00.000ZClinical features, diagnosis, and treatment of colorectal cap polyposishttps://www.pharmaradar360.com/article/unraveling-the-regulatory-mechanisms-of-tetrandrine-in-microglial-phenotypic-tra-ce6185886114adc2Pharma Surgeen2026-06-27T00:00:00.000ZUnraveling the regulatory mechanisms of tetrandrine in microglial phenotypic transition and neuronal autophagy for relieving diabetic neuropathic painhttps://www.pharmaradar360.com/article/a-clinical-study-on-patterns-of-vernal-keratoconjunctivitis-among-children-in-ru-0a5bbb084aa6349bPharma Surgeen2026-06-27T00:00:00.000ZA clinical study on patterns of vernal keratoconjunctivitis among children in rural part of North-East Indiahttps://www.pharmaradar360.com/article/assessment-of-health-related-quality-of-life-and-drug-related-problems-in-cardio-dd46397e1f288a6fPharma Surgeen2026-06-27T00:00:00.000ZAssessment of Health-Related Quality of Life and Drug-Related Problems In Cardiometabolic Patients In A Tertiary Care Hospitalhttps://www.pharmaradar360.com/article/the-impact-of-electronic-media-marketing-on-startup-growth-and-sustainability-285452ad2761fabbPharma Surgeen2026-06-27T00:00:00.000ZThe Impact Of Electronic Media Marketing On Startup Growth And Sustainabilityhttps://www.pharmaradar360.com/article/brand-building-in-the-digital-age-the-role-of-social-media-engagement-and-influe-16e0b04ca61b1643Pharma Surgeen2026-06-27T00:00:00.000ZBrand Building In The Digital Age: The Role Of Social Media Engagement And Influencer Marketinghttps://www.pharmaradar360.com/article/climate-smart-agriculture-and-sustainable-farming-practices-in-bastar-chhattisga-081b905b9a87d0b2Pharma Surgeen2026-06-27T00:00:00.000ZClimate-Smart Agriculture and Sustainable Farming Practices in Bastar, Chhattisgarh: Assessing Farmers’ Attitudes Toward Technology Adoptionhttps://www.pharmaradar360.com/article/quality-by-design-based-development-of-clindamycin-and-curcumin-drug-loaded-lipo-06fb382a7859c6c5Pharma Surgeen2026-06-27T00:00:00.000ZQuality by Design-Based Development of Clindamycin and Curcumin Drug-Loaded Lipospheres for Improved Topical Delivery and Antibacterial Efficacyhttps://www.pharmaradar360.com/article/formulation-and-evaluation-of-nanoemulsion-of-rasagiline-mesylate-for-its-anti-p-8c43e00db6d9b5e1Pharma Surgeen2026-06-27T00:00:00.000ZFormulation and Evaluation of Nanoemulsion of Rasagiline Mesylate for its anti-Parkinson efficacyhttps://www.pharmaradar360.com/article/surface-treatments-and-thermocycling-effects-on-the-fracture-resistance-and-marg-3577f91194e03c02Pharma Surgeen2026-06-27T00:00:00.000ZSurface treatments and thermocycling effects on the fracture resistance and marginal adaptation of veneering systems on yttrium stabilized tetragonal zirconia polycrystal: An In-vitro studyhttps://www.pharmaradar360.com/article/multilingual-indic-cyberbullying-detection-with-text-meme-fusion-severity-gradin-e264f8169e24d50cPharma Surgeen2026-06-27T00:00:00.000ZMultilingual Indic Cyberbullying Detection with Text-Meme Fusion, Severity Grading, LIME Explainability, and RealTime Streamlit Deploymenthttps://www.pharmaradar360.com/article/witness-protection-in-india-legislative-deficit-empirical-dimensions-comparative-8b6a94e7e3b64404Pharma Surgeen2026-06-27T00:00:00.000ZWitness Protection In India: Legislative Deficit, Empirical Dimensions, Comparative Models, And The Imperative Of Parliamentary Legislationhttps://www.pharmaradar360.com/article/early-hypotonia-as-a-presentation-of-evolving-spastic-palsy-a-case-report-b824cdb55a668cb8Pharma Surgeen2026-06-27T00:00:00.000ZEarly Hypotonia as a Presentation of Evolving Spastic Palsy - A case reporthttps://www.pharmaradar360.com/article/non-pharmacological-behavior-management-techniques-in-pediatric-dentistry-a-narr-97f2c054f1d7ee10Pharma Surgeen2026-06-27T00:00:00.000ZNon-pharmacological behavior management techniques in pediatric dentistry: A narrative&amp;amp;nbsp;&amp;lt;span style=&amp;quot;font-size: 1rem;&amp;quot;&amp;gt;review and clinical insights&amp;lt;/span&amp;gt;https://www.pharmaradar360.com/article/genital-fungal-infections-in-type-2-diabetes-clinical-behavioral-and-microbiota-d4c181befa4c2587Pharma Surgeen2026-06-27T00:00:00.000ZGenital fungal infections in type 2 diabetes: Clinical, behavioral, and microbiota correlates of SGLT2 inhibitor therapyhttps://www.pharmaradar360.com/article/characterization-of-serotypes-diversity-and-drug-susceptibiliy-among-clinical-sa-8c65b0558d6aadaePharma Surgeen2026-06-27T00:00:00.000ZCharacterization of serotypes, diversity and drug susceptibiliy among clinical Salmonella isolateshttps://www.pharmaradar360.com/article/romanian-national-study-on-the-epidemiology-of-inflammatory-bowel-diseases-3b7fbe0ea9d438b1Pharma Surgeen2026-06-27T00:00:00.000ZRomanian National Study on the Epidemiology of Inflammatory Bowel Diseaseshttps://www.pharmaradar360.com/article/clinical-research-trends-of-laser-therapy-for-onychomycosis-in-korea-china-and-j-7ac2c9b76fda70a4Pharma Surgeen2026-06-27T00:00:00.000ZClinical Research Trends of Laser Therapy for Onychomycosis in Korea, China, and Japan, and Its Applicability in Korean Medicine: A Scoping Reviewhttps://www.pharmaradar360.com/article/clinical-research-trends-in-lidocaine-injection-at-acupoints-a-scoping-review-ee10725939281363Pharma Surgeen2026-06-27T00:00:00.000ZClinical Research Trends in Lidocaine Injection at Acupoints: A Scoping Reviewhttps://www.pharmaradar360.com/article/design-synthesis-and-biological-evaluation-of-potent-cognition-improved-compound-8a79ca0d704d94c6Pharma Surgeen2026-06-27T00:00:00.000ZDesign, Synthesis, and Biological Evaluation of Potent Cognition-Improved Compounds Targeting AMPA Receptor Based on CX717https://www.pharmaradar360.com/article/an-improved-brain-penetrating-nanoformulation-of-the-vipr2-antagonist-peptide-ks-db52ea4f755326c3Pharma Surgeen2026-06-27T00:00:00.000ZAn Improved Brain-Penetrating Nanoformulation of the VIPR2 Antagonist Peptide KS-133 for Treating Cognitive Impairment in Schizophreniahttps://www.pharmaradar360.com/article/approach-to-personalizing-the-treatment-of-osteoporosis-ac83e69b76f0b124Pharma Surgeen2026-06-27T00:00:00.000ZApproach to Personalizing the Treatment of Osteoporosishttps://www.pharmaradar360.com/article/nonpharmacological-multicomponent-intervention-for-mild-cognitive-impairment-wit-5395f9c821b0153bPharma Surgeen2026-06-27T00:00:00.000ZNonpharmacological multicomponent intervention for mild cognitive impairment with a family-patient approach: protocol for the pilot clinical trial—INTERCOG studyhttps://www.pharmaradar360.com/article/clinical-outcomes-of-capsular-repair-versus-non-repair-after-hip-arthroscopy-for-a467b39792de6737Pharma Surgeen2026-06-27T00:00:00.000ZClinical outcomes of capsular repair versus non-repair after hip arthroscopy for femoroacetabular impingement: a meta-analysishttps://www.pharmaradar360.com/article/investigating-the-effect-of-intermittent-fasting-time-restricted-eating-with-and-2fbc59c1fec62889Pharma Surgeen2026-06-27T00:00:00.000ZInvestigating the effect of intermittent fasting (time-restricted eating) with and without calorie restriction compared to calorie restriction on anthropometric parameters, depression score, and metabolic factors in patients with major depression disorder and obesity: a study protocol for a randomizhttps://www.pharmaradar360.com/article/multidisciplinary-telemedicine-intervention-for-icu-recovery-the-teleport-feasib-0fea1b9c346de16aPharma Surgeen2026-06-27T00:00:00.000ZMultidisciplinary telemedicine intervention for ICU recovery: the TelePORT feasibility randomized trialhttps://www.pharmaradar360.com/article/epigenetic-safety-of-in-vitro-maturation-in-pcos-genome-wide-dna-methylation-pro-34f393033c3513d3Pharma Surgeen2026-06-27T00:00:00.000ZEpigenetic safety of in vitro maturation in PCOS: genome-wide DNA methylation profiling of cord blood from a randomized controlled trialhttps://www.pharmaradar360.com/article/hes1-inhibition-overcomes-cdk4-6-inhibitor-resistance-by-targeting-cancer-stemne-5cba035ccea18361Pharma Surgeen2026-06-27T00:00:00.000ZHES1 inhibition overcomes CDK4/6 inhibitor resistance by targeting cancer stemness in lung adenocarcinomahttps://www.pharmaradar360.com/article/from-paradox-to-target-ifn-hijacks-mek-signaling-to-drive-a-cell-death-evading-d-e4766fc05fd00c73Pharma Surgeen2026-06-27T00:00:00.000ZFrom paradox to target: IFN-β hijacks MEK signaling to drive a cell death-evading dormant phenotype in colorectal cancerhttps://www.pharmaradar360.com/article/nasal-eosinophilia-in-pediatric-non-allergic-rhinitis-correlation-with-clinical-405c845055f12ad6Pharma Surgeen2026-06-27T00:00:00.000ZNasal eosinophilia in pediatric non-allergic rhinitis: correlation with clinical severity scaleshttps://www.pharmaradar360.com/article/integrated-analysis-of-gut-microbiota-serum-metabolomics-and-proteomics-reveals-ed3a2176378e6788Pharma Surgeen2026-06-27T00:00:00.000ZIntegrated analysis of gut microbiota, serum metabolomics, and proteomics reveals novel associations with clinical symptoms in patients with cerebral infarctionhttps://www.pharmaradar360.com/article/clinical-resource-quick-reference-5218649929da5506Pharma Surgeen2026-06-27T00:00:00.000ZClinical Resource/Quick Referencehttps://www.pharmaradar360.com/article/temporal-changes-in-left-ventricular-strain-in-typical-and-atypical-left-bundle-df939561b7f0c0f6Pharma Surgeen2026-06-27T00:00:00.000ZTemporal Changes in Left Ventricular Strain in Typical and Atypical Left Bundle Branch Block Patients: A Follow‐up Studyhttps://www.pharmaradar360.com/article/synergistic-cardioprotection-of-colchicine-and-hyperbaric-oxygen-therapy-in-a-ra-377fc1f80300d6b7Pharma Surgeen2026-06-27T00:00:00.000ZSynergistic Cardioprotection of Colchicine and Hyperbaric Oxygen Therapy in a Rat Model of Remote Ischemia‐Reperfusion Injuryhttps://www.pharmaradar360.com/article/a-novel-device-to-improve-the-tolerability-of-intranasal-corticosteroid-sprays-f-e9eb0fb571453af3Pharma Surgeen2026-06-27T00:00:00.000ZA Novel Device to Improve the Tolerability of Intranasal Corticosteroid Sprays for Allergic Rhinitis and Postoperative Chronic Rhinosinusitis: A Crossover Trialhttps://www.pharmaradar360.com/article/modulation-of-respiratory-diseases-by-the-endocannabinoid-system-a-therapeutic-p-6870a9d8b8234ab0Pharma Surgeen2026-06-27T00:00:00.000ZModulation of Respiratory Diseases by the Endocannabinoid System: A Therapeutic Perspectivehttps://www.pharmaradar360.com/article/feasibility-and-process-evaluation-of-cardiac-brief-intervention-cabin-in-patien-520ff6325fd07b07Pharma Surgeen2026-06-27T00:00:00.000ZFeasibility and Process Evaluation of CArdiac Brief INtervention (CABIN) in Patients with ST-Elevation Myocardial Infarction: A Mixed-Method, Pilot Randomised Controlled Trial.https://www.pharmaradar360.com/article/right-ventricular-to-pulmonary-artery-coupling-and-clinical-outcomes-after-inter-ffe6ad9490ef4a71Pharma Surgeen2026-06-27T00:00:00.000ZRight Ventricular to Pulmonary Artery Coupling and Clinical Outcomes after Interatrial Shunting in Heart Failure: Exploratory Analysis of the PRELIEVE studyhttps://www.pharmaradar360.com/article/rivaroxaban-for-the-prevention-of-atherothrombotic-events-in-advanced-ckd-are-we-2791af078868ef70Pharma Surgeen2026-06-27T00:00:00.000ZRivaroxaban for the prevention of atherothrombotic events in advanced CKD: are we off TRACK?https://www.pharmaradar360.com/article/case-series-on-the-efficacy-of-daratumumab-in-treating-patients-with-anti-interf-8f14c2797d2a2d7ePharma Surgeen2026-06-27T00:00:00.000ZCase Series on the Efficacy of Daratumumab in Treating Patients with Anti-Interferon-Gamma Autoantibodieshttps://www.pharmaradar360.com/article/a-second-case-of-recessive-mosaicism-in-i-abca12-i-causing-a-congenital-unilater-53752a1fcce64379Pharma Surgeen2026-06-27T00:00:00.000ZA second case of recessive mosaicism in <i>ABCA12</i> causing a congenital unilateral epidermal nevushttps://www.pharmaradar360.com/article/hydrogel-based-drug-delivery-systems-for-oral-mucositis-a-systematic-review-of-p-e5b1001ffb49356fPharma Surgeen2026-06-27T00:00:00.000ZHydrogel-based drug delivery systems for oral mucositis: a systematic review of preclinical models and translational perspectiveshttps://www.pharmaradar360.com/article/using-nal-nl3-in-clinical-practice-a-modular-nal-fitting-system-for-real-world-l-9f0e6bd53e8247e5Pharma Surgeen2026-06-27T00:00:00.000ZUsing NAL-NL3 in clinical practice: a modular NAL fitting system for real-world listening needshttps://www.pharmaradar360.com/article/patient-derived-organoids-as-a-predictive-platform-for-drug-sensitivity-in-bladd-b81aa48238e6fa41Pharma Surgeen2026-06-27T00:00:00.000ZPatient-derived organoids as a predictive platform for drug sensitivity in bladder cancerhttps://www.pharmaradar360.com/article/screen-for-tissue-specific-markers-of-drug-induced-phospholipidosis-using-mass-s-ca6722ad21ef4967Pharma Surgeen2026-06-27T00:00:00.000ZScreen for Tissue-Specific Markers of Drug-Induced Phospholipidosis Using Mass Spectrometry Imaginghttps://www.pharmaradar360.com/article/the-care-program-an-initiative-of-patient-focused-drug-development-for-rare-dise-69a1013a68a9f822Pharma Surgeen2026-06-27T00:00:00.000ZThe CARE Program: An Initiative of Patient-Focused Drug Development for Rare Diseases by NMPAhttps://www.pharmaradar360.com/article/prevalence-predictors-and-clinical-impact-of-vitamin-d-deficiency-on-12-month-ou-3c09360b6bdb5bc7Pharma Surgeen2026-06-27T00:00:00.000ZPrevalence, predictors, and clinical impact of vitamin D deficiency on 12-month outcomes in hip fracture patientshttps://www.pharmaradar360.com/article/multiple-drugs-0959bbed11907609Pharma Surgeen2026-06-27T00:00:00.000ZMultiple drugshttps://www.pharmaradar360.com/article/methadone-b51c16fb2734b6ecPharma Surgeen2026-06-27T00:00:00.000ZMethadonehttps://www.pharmaradar360.com/article/fluoxetine-lamotrigine-9ce06871f2cf2c17Pharma Surgeen2026-06-27T00:00:00.000ZFluoxetine/Lamotriginehttps://www.pharmaradar360.com/article/redispersible-nanoalum-adjuvanted-hepatitis-b-vaccine-microneedles-with-enhanced-be904797ec2b070cPharma Surgeen2026-06-27T00:00:00.000ZRedispersible nanoalum-adjuvanted hepatitis B vaccine microneedles with enhanced immunogenicityhttps://www.pharmaradar360.com/article/transparent-keratin-nanocomposite-films-incorporating-silver-nanoparticles-and-a-90028a257c9644d4Pharma Surgeen2026-06-27T00:00:00.000ZTransparent keratin nanocomposite films incorporating silver nanoparticles and aloe vera for wound managementhttps://www.pharmaradar360.com/article/traditional-buddhist-mindfulness-versus-secular-mindfulness-based-cognitive-ther-e8b5e1fd01d1a3daPharma Surgeen2026-06-27T00:00:00.000ZTraditional Buddhist Mindfulness Versus Secular Mindfulness-Based Cognitive Therapy for Residual Depressive Symptoms in Patients Treated for Depressive Disorder: A Pilot Randomized Controlled Trialhttps://www.pharmaradar360.com/article/optimizing-tourniquet-pressures-in-knee-arthroscopy-an-international-survey-on-c-97f4d62f790853ccPharma Surgeen2026-06-27T00:00:00.000ZOptimizing tourniquet pressures in knee arthroscopy: an international survey on current practice and a double-blind randomized trialhttps://www.pharmaradar360.com/article/pharmacogenomic-characterization-of-a-uric-acid-metabolism-related-signature-ass-f942d473ac21324aPharma Surgeen2026-06-27T00:00:00.000ZPharmacogenomic characterization of a uric acid metabolism-related signature associated with prognosis and drug sensitivity in gastric cancerhttps://www.pharmaradar360.com/article/bovine-milk-derived-extracellular-vesicles-as-emerging-drug-delivery-platforms-c-fa2f6cddbf9d313aPharma Surgeen2026-06-27T00:00:00.000ZBovine Milk–Derived Extracellular Vesicles as Emerging Drug Delivery Platforms: Current Advances, Applications and Challengeshttps://www.pharmaradar360.com/article/clinical-pharmacists-in-primary-care-a-real-world-experience-from-sao-paulo-braz-172804bcc1ea7cfePharma Surgeen2026-06-27T00:00:00.000ZClinical Pharmacists in Primary Care: A Real‐World Experience From São Paulo, Brazilhttps://www.pharmaradar360.com/article/the-permissible-use-of-the-pernkopf-atlas-a-single-case-qualitative-study-of-the-3ab7aee9344e4ad2Pharma Surgeen2026-06-27T00:00:00.000ZThe Permissible Use of the Pernkopf Atlas: A Single‐Case Qualitative Study of the Vienna Protocolhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-suzhou-fengbei-biotech-stock-co-ltd-class-a-sse-603-ec5fc02873ee8949Pharma Surgeen2026-06-26T23:59:52.000ZPrice to earnings forward of Suzhou Fengbei Biotech Stock Co., Ltd. Class A – SSE:603334https://www.pharmaradar360.com/article/ema-amgen-vifor-inflammatory-drug-s-benefits-no-longer-outweigh-risks-80766860202ba693Pharma Surgeen2026-06-26T23:43:22.000ZEMA: Amgen, Vifor Inflammatory Drug’s Benefits No Longer Outweigh Riskshttps://www.pharmaradar360.com/article/fda-approves-viridian-s-lumvoa-for-thyroid-eye-disease-ted-3d8a3db7e83dfc37Pharma Surgeen2026-06-26T23:24:14.000ZFDA Approves Viridian's Lumvoa for Thyroid Eye Disease (TED)https://www.pharmaradar360.com/article/this-biotech-etf-has-almost-doubled-in-13-months-money-is-flowing-in-barrons-com-6995c9ff64865e07Pharma Surgeen2026-06-26T23:21:39.000ZThis Biotech ETF Has Almost Doubled in 13 Months. Money Is Flowing In. -- Barrons.comhttps://www.pharmaradar360.com/article/pioneering-projects-to-transform-obesity-care-backed-by-85-million-from-governme-0e7a0d3c28749fdbPharma Surgeen2026-06-26T23:01:04.000ZPioneering projects to transform obesity care, backed by £85 million from government and industryhttps://www.pharmaradar360.com/article/fda-approves-viridian-eye-drug-stoking-competition-with-amgen-s-tepezza-a76c58731188bb4bPharma Surgeen2026-06-26T22:52:00.000ZFDA approves Viridian eye drug, stoking competition with Amgen’s Tepezzahttps://www.pharmaradar360.com/article/medpace-medp-has-a-backlog-and-execution-engine-bigger-than-a-biotech-funding-sc-b4901212b3a8b375Pharma Surgeen2026-06-26T22:39:25.000ZMedpace (MEDP) Has a Backlog-and-Execution Engine Bigger Than a Biotech-Funding Scarehttps://www.pharmaradar360.com/article/argentina-joins-chinese-coronavirus-vaccine-trial-a20d7d9f67a80cb6Pharma Surgeen2026-06-26T22:38:56.000ZArgentina joins Chinese coronavirus vaccine trialhttps://www.pharmaradar360.com/article/appili-therapeutics-reports-fiscal-year-2026-financial-and-operational-results-b0ea0694454f3562Pharma Surgeen2026-06-26T22:32:32.000ZAppili Therapeutics Reports Fiscal Year 2026 Financial and Operational Resultshttps://www.pharmaradar360.com/article/viridian-therapeutics-announced-that-its-innovative-drug-lumvoatm-generic-name-v-6430e5dafa92352cPharma Surgeen2026-06-26T22:24:57.000ZViridian Therapeutics announced that its innovative drug Lumvoa™ (generic name: veligrotug-vvze) has been approved by the U.S. Food and Drug Administration (FDA) and officially launched for the treatment of Thyroid Eye Disease (TED).https://www.pharmaradar360.com/article/price-to-earnings-forward-of-sunhawk-vision-biotech-inc-tpex-7759-adf6cf8c0a4b9eefPharma Surgeen2026-06-26T22:21:52.000ZPrice to earnings forward of Sunhawk Vision Biotech, Inc. – TPEX:7759https://www.pharmaradar360.com/article/is-axsome-therapeutics-axsm-using-solriamfetol-s-phase-3-adhd-trial-to-redefine-cc15412b63944483Pharma Surgeen2026-06-26T22:17:29.000ZIs Axsome Therapeutics (AXSM) Using Solriamfetol’s Phase 3 ADHD Trial To Redefine Its CNS Strategy?https://www.pharmaradar360.com/article/viridian-therapeutics-announces-u-s-fda-approval-and-launch-of-lumvoatm-veligrot-bf58f9dd4693a86aPharma Surgeen2026-06-26T22:00:00.000ZViridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Diseasehttps://www.pharmaradar360.com/article/more-than-900-000-bottles-of-heart-and-kidney-drugs-recalled-fda-notice-782c790d59fe0f29Pharma Surgeen2026-06-26T21:40:19.000ZMore Than 900,000 Bottles of Heart and Kidney Drugs Recalled: FDA Noticehttps://www.pharmaradar360.com/article/lantheus-stock-falls-after-fda-rejects-drug-application-3226385a0511d32fPharma Surgeen2026-06-26T21:30:12.000ZLantheus stock falls after FDA rejects drug applicationhttps://www.pharmaradar360.com/article/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-5233053c00e4101fPharma Surgeen2026-06-26T21:15:00.000ZMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliancehttps://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-stock-outperforms-competitors-on-strong-trading-3f486c113376e67aPharma Surgeen2026-06-26T21:02:00.000ZWest Pharmaceutical Services Inc. stock outperforms competitors on strong trading dayhttps://www.pharmaradar360.com/article/fda-will-reportedly-conclude-abortion-pill-safety-review-by-september-794bb91f5c6a106dPharma Surgeen2026-06-26T21:01:08.000ZFDA Will Reportedly Conclude Abortion Pill Safety Review by Septemberhttps://www.pharmaradar360.com/article/universe-pharmaceuticals-inc-announces-strategic-acquisition-to-expand-pharmaceu-73968fa9437dd07cPharma Surgeen2026-06-26T20:58:14.000ZUniverse Pharmaceuticals Inc Announces Strategic Acquisition To Expand Pharmaceutical Patent Portfoliohttps://www.pharmaradar360.com/article/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-diseas-3181bcc3d02f16abPharma Surgeen2026-06-26T20:50:00.000ZSKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Diseasehttps://www.pharmaradar360.com/article/swiss-pharma-at-risk-of-us-trade-investigation-industry-body-says-845e46620aff05f9Pharma Surgeen2026-06-26T20:41:16.000ZSwiss pharma at risk of US trade investigation, industry body sayshttps://www.pharmaradar360.com/article/neuphoria-responds-to-the-announcement-made-by-london-listed-scancell-holdings-p-5c46e0083e57cb26Pharma Surgeen2026-06-26T20:31:36.000ZNeuphoria Responds to the announcement made by London-listed Scancell Holdings plchttps://www.pharmaradar360.com/article/abbvie-inc-stock-abbv-closed-up-by-3-53-on-jun-26-facts-behind-the-movement-b7f45eb71dc1d8d8Pharma Surgeen2026-06-26T20:15:28.000ZAbbVie Inc Stock (ABBV) Closed Up by 3.53% on Jun 26: Facts Behind the Movementhttps://www.pharmaradar360.com/article/swiss-pharmaceutical-industry-faces-potential-us-trade-investigation-68563507026fcb7aPharma Surgeen2026-06-26T20:15:23.000ZSwiss pharmaceutical industry faces potential US trade investigationhttps://www.pharmaradar360.com/article/monopar-presents-new-analyses-of-phase-3-focus-data-at-ean-2026-showing-greater-c896051b7b879963Pharma Surgeen2026-06-26T20:11:28.000ZMonopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Diseasehttps://www.pharmaradar360.com/article/lantheus-receives-complete-response-letter-from-fda-for-lnth-2501-ga-68-edotreot-8c44a04a5c8e0368Pharma Surgeen2026-06-26T20:11:24.000ZLantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)https://www.pharmaradar360.com/article/alxn1840-phase-3-data-back-nda-plan-for-wilson-disease-monopar-nasdaq-mnpr-c60111e02ac821f7Pharma Surgeen2026-06-26T20:07:07.000ZALXN1840 Phase 3 data back NDA plan for Wilson disease, Monopar (NASDAQ: MNPR)https://www.pharmaradar360.com/article/monopar-s-wilson-disease-drug-shows-stronger-neurologic-gains-in-phase-3-a3d3cd8a027d1771Pharma Surgeen2026-06-26T20:05:00.000ZMonopar’s Wilson disease drug shows stronger neurologic gains in Phase 3